COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020

Link to article at PubMed

Open Forum Infect Dis. 2020 Nov 9;7(11):ofaa528. doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.


Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.

PMID:33274249 | PMC:PMC7686662 | DOI:10.1093/ofid/ofaa528

Leave a Reply

Your email address will not be published. Required fields are marked *